AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

What happened: Summit Therapeutics announced the closing of AstraZeneca's strategic equity investment in the company. The funds will support accelerated development of ivonescimab, an investigational PD-1 / VEGF bispecific antibody. Key numbers: Investment totaled $2.0 billion. Why it matters: Summit said the funds allow accelerated development of ivonescimab across solid tumor settings, including combinations with ADCs such as sonesitatug vedotin and Datroway. The chairman said the investment reflects AstraZeneca's confidence in ivonescimab's potential.

Summit Therapeutics announced the closing of AstraZeneca's strategic equity investment in the company. The funds will support accelerated development of ivonescimab, an investigational PD-1 / VEGF bispecific antibody.

Summit said the funds allow accelerated development of ivonescimab across solid tumor settings, including combinations with ADCs such as sonesitatug vedotin and Datroway. The chairman said the investment reflects AstraZeneca's confidence in ivonescimab's potential.